End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
19,900 KRW | +1.12% | +5.74% | -3.63% |
Apr. 24 | Korean Sugar Imports Plunge 14% as Diabetes Cases Surge | MT |
Mar. 08 | Daewoong Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 432.34 for the 2024 fiscal year.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-3.63% | 596M | - | ||
+18.67% | 43.74B | B- | ||
+21.99% | 22.26B | B+ | ||
+16.41% | 14.9B | - | ||
+9.03% | 13.39B | B+ | ||
+40.48% | 12.12B | B | ||
-9.64% | 6.92B | B+ | ||
-0.05% | 6.79B | - | - | |
-8.87% | 5.73B | - | - | |
+12.41% | 5.47B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- A003090 Stock
- Ratings Daewoong Co., Ltd.